Morphosys Seeks US Listing To Cement Corporate Developments

German biotech Morphosys has filed an F-1 registration statement with the US Securities & Exchange Commission to list the ADSs on the Nasdaq Global Market to raise its profile among US investors and raise up to $150m. Funds will primarily be used to support the company’s ambitions to commercialize MOR208 in the US.